# MEDIOLA (NCT02734004)

> A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02734004
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Ovarian; Breast; SCLC; Gastric Cancers
- Interventions: Olaparib; MEDI4736; Bevacizumab
- Enrollment: 264
- Primary outcome: Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12
- Primary outcome: Second Stage Cohort: Objective Response Rate (ORR)
- Primary outcome: Second Stage Cohorts: DCR at Week 24

## Commentary we found

- YouTube: 12
- Podcasts: 10
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=mediola-nct02734004

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02734004", "email": "<work email>"}; the inbox owner confirms by the emailed link.